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Abstract 
Methionine demethylation during metabolism generates homocysteine (Hcy) and its remethylation requires 
folate and cobalamin.   Elevated Hcy concentrations are associated with vascular-related complications of 
pregnancy, including increased vascular stiffness, predictive of clinical vascular disease. Maternal and fetal 
total Hcy (tHcy) concentrations are positively related, yet the influence of Hcy on fetoplacental vascular 
function in normal pregnancy has not been examined. We hypothesized that Hcy alters fetoplacental vascular 
characteristics with influences on fetal growth outcomes. We investigated (1) placental chorionic plate 
artery distensibility and neonatal blood pressure in relation to umbilical plasma tHcy; (2) relationships between 
cord venous (CV) and cord arterial (CA) plasma tHcy, folate, and cobalamin concentrations; and (3) tHcy 
associations with birth weight and anthropometric measurements of body size as indices of fetal growth 
in normal pregnancies with appropriate weight-for-gestational age newborns. Maternal plasma tHcy, 
folate, and cobalamin concentrations were consistent with published data. Placental chorionic plate artery 
distensibility index (β; measure of vessel stiffness) was inversely related to CA tHcy, yet neonatal blood pressure 
was not significantly affected. CV and CA tHcy concentrations were positively related and CV tHcy 
negatively related to CV cobalamin but not folate. CV tHcy concentration positively related to birth 
weight, corrected birth weight per-centile, length, head circumference, and mid-arm circumference of 
newborns. CV cobalamin was inversely related to fetal growth indices but not to folate concentration. Our 
study demonstrates a potential relationship between fetal tHcy and placental artery distensibility, placing 
clinical relevance to cobalamin in influencing Hcy concentration and maintaining low vascular resistance to  
facilitate nutrient exchange favorable to fetal growth.  
 
Introduction  
Homocysteine (Hcy) arises from the metabolism of methionine (Figure 1), which crucially generates the 
methyl donor S-adenosylmethionine (SAM) required for cellular methylation processes including 
DNA, RNA, protein, and phospholipid methylation.1 Methyl donation from SAM to cellular 
acceptors generates S-adenosylhomocysteine (SAH). The efficient metabolism of SAH (by SAH 
hydrolase catalysis to produce adenosine and Hcy) is essential, as SAH inhibits the activity of SAM-
dependent methyltransferases involved in a variety of methylation reactions. Homocysteine can 
undergo remethylation back to methionine (Figure 1), and this conversion requires folate and 
cobalamin (Cbl) catalyzed by the action of methionine synthase.1,2 Importantly, this is the main 
pathway for the metabolic disposal of Hcy in human placenta.1 Hence, suboptimal folate or Cbl 
status, or diminished Hcy-metabolizing enzyme activity, can lead to dysregulated Hcy biosynthesis 
and elevated plasma total Hcy (tHcy) concentration.3-5 Human pregnancy is a period of increased 
folate and Cbl demand6 and disturbances in Hcy-folate-Cbl metabolism associate with clinical 
complications affecting uteroplacental vascular function with impacts on fetal and neonatal 
development.7-10  
 
Several studies have demonstrated that maternal tHcy concentration is higher in infants of low birth 
weight than normal controls,8,11-14 and a meta-analysis has revealed a 25% increased risk of 
having a small-for-gestational age infant when maternal tHcy concentration exceeded the 90th 
percentile.11 However, observations are inconsistent; other studies report that low birth weight is 
not associated with raised maternal tHcy concentration15,16 or demonstrate both negative17 and 
positive18 associations between maternal tHcy concentration and birth weight. A consistent 
interpretation of these data is challenging, as effects of tHcy on birth weight per se may not be 
easily distinguished from effects of accompanying suboptimal B vitamin status that would 
generate tHcy through metabolic-interdependent pathways (Figure 1). A more informative 
situation is presented when availability of maternal folate and Cbl is optimal, and therefore, fetal 
provision of these is not limiting, in determining the relationship between tHcy and fetal growth 
outcomes. 
 
Raised tHcy is an independent risk factor for vascular disease19,20; it associates with several 
aspects of impaired vascular function including endothelial dysfunction,4,21-23 enhanced 
smooth muscle proliferation,24 stimulated collagen biosynthesis,25,26 and diminished vascular 
elasticity,27 leading to increased arterial stiffness. However, much remains to be understood about 
the potential relationship between tHcy and indices of arterial stiffness in the fetoplacental 
circulation in normal pregnancy. 
 
We hypothesized that as fetal Hcy increases, distensible properties of arteries in the fetoplacental 
circulation would be impaired, leading to an increased vascular resistance, which in turn could 
influence fetal growth and vascular indices in the neonate. Hence, a primary objective of this study 
was to investigate whether cord plasma tHcy concentrations influence the distensibility 
characteristics of small chorionic plate arteries (CPAs) of human placenta, selected for their 
relative ease of accessibility and a likely site of resistance in the fetoplacental circulation.28-30 
Additionally, we examined whether neonatal blood pressure (BP), as an index of vascular 
resistance, was influenced by fetal tHcy concentration and determined the relationships between fetal 
tHcy in umbilical cord venous (CV) and cord arterial (CA) plasma to birth weight and anthropometric 
measures of neonatal body proportions. 
 
Materials and Methods 
Mothers 
All women (European, white Caucasian) were in good health and gave signed informed consent at St 
Maƌy͛s Hospital, MaŶchester. Ethical approval was granted by the Central Manchester 
Local Research Ethics Committee (06/Q1407/25) with University of Manchester Committee on the 
Ethics of Research on Human Beings endorsement (06040). Obstetric records confirmed normal 
uncomplicated pregnancies. Maternal characteristics were obtained at the first antenatal clinic 
attendance (10-12 weeks). Gestational age was defined as completed weeks of gestation, using 
menstrual dates and confirmed by ultrasound dating. The women reported routine use of folic acid 
supplements (0.4 mg/d, 4-8 weeks duration in early pregnancy), a non-vegetarian diet, and not 
smoking cigarettes. 
 
Newborn Infants, Anthropometric Measurements, and BP 
All infants were in good condition at birth (Apgar scores 9 or 10 at 1 minute). Percentiles for birth 
weight were determined using national growth standards (UK-WHO Growth Charts for Children 
aged 0-4 years, Child Growth Foundation, UK). On routine clinical examination, no medical condition 
or congenital abnormality was recorded. The same research nurse measured birth weight using a 
digital baby scale (Seca  384, Germany) and anthropometric indices. Occipital-frontal head 
circumference and mid-arm circumference with the left arm flexed to 90 at the elbow were 
measured using a paper measuring tape. Length was measured using a Harpenden Neonatometer 
(Holtain Limited, United Kingdom). Blood pressure was measured using a Dinamap Pro 100 
automated oscillometric machine with an appropriate BP cuff (GE Medical Systems, Information 
Technologies, Freiburg, Germany) at 24 to 48 hours following birth.31 
 
Plasma tHcy, Folate, and Cbl Analysis 
Non-fasting maternal blood was obtained from the antecubital vein at antenatal clinic (10-12 
weeks). The CV and CA blood was obtained at delivery after clamping the umbilical cord. 
Maternal and cord blood was collected into tubes with either potassium EDTA or lithium heparin as 
anticoagulant, placed on ice, and centrifuged at 1000g for 10 minutes. Separated plasma was 
stored at 80 C and transferred for analysis (University Hospital of Wales, Cardiff). Plasma tHcy was 
measured by high-performance liquid chromatography and fluorometric detection following 
reduction, deproteinization, and derivatization with the fluorophore SBDF (ammonium 7-fluorobenzo-
2-oxa-1,3-diazole-4-sullfonate).32 This assay was standardized using National Institute of Standards 
and Technology Standard Reference Material. Plasma folate and Cbl were measured by competitive 
protein-binding assays on an Elecys 2010 analyzer (Roche Diagnostics, Burgess Hill, West Sussex, UK). 
 
Pressure Myography Studies on CPAs 
Pressure myography studies were performed to measure the passive mechanical wall properties of 
the CPAs.30,33 Placentas were obtained within 30 minutes of delivery, and CPAs (<300 mm diameter) 
were isolated and mounted onto 2 glass cannulae connected to a pressure servo unit to regulate 
transmural pressure (Living Systems Instrumentation, Burlington, Vermont). The arteriography 
chamber was perfused with calcium-free physiological solution (with the following composition 
[in mmol/L]: NaCl 119, NaHCO3  25, KCl 4.69, MgSO4  2.4, EGTA 2, KH2PO4 1.18, glucose 6.05, 
EDTA 0.034, pH 7.4; gassed with 5% O2 and 5% CO2) and maintained at 37oC. Intraluminal 
pressure was increased stepwise from 3 to 120 mm Hg. Vessels were continuously analyzed by 
video dimension analysis, and arterial lumen diameter and wall thicknesses were measured at 3 
sites along the vessel length (and averaged). Wall cross-sectional area (CSA) was calculated as 
pðr0 r1Þ, where r0 and r1 are whole vessel and lumen radii, respectively. These measurements 
allowed calculation of wall stress and strain. Wall stress (dyne/cm2) was calculated as: pressure 
lumen diameter/(2 wall thickness). Strain was calculated as: increase in lumen diameter from 3 mm 
Hg/diameter at 3 mm Hg. From plots of the stress-strain relationship (r2 > .9), where stress = 
y.eβ.strain, the coefficient of intrinsic vessel stiffness (b) was derived from the gradient. 
 
Data Analysis 
Statistical analyses were carried out with SPSS 11.0 for Windows (IBM SPSS, Portsmouth, Hampshire, 
UK) or Prism version 6 (GraphPad Software, La Jolla, California). Data are presented in various 
formats as detailed in the text, with n = number of individual pregnancies. Birth weight was adjusted 
for maternal height, weight, ethnicity and parity, infant sex, and gestational age to determine 
corrected birth weight percentile.34     Median tHcy, folate, and Cbl values in CV and CA blood were 
compared using Mann-Whitney U or Wilcoxon signed rank test as appropriate. Spearman correlation 
coefficient was used to investigate relationships of CV plasma tHcy, folate, or Cbl with birth weight 
and anthropometric measurements; relationship of CV and CA plasma tHcy with systolic, diastolic, or 
mean BP; and relationship between CA plasma tHcy and CPA stiffness index (β). Linear regression 
analysis was used to examine the relationship between paired CV and CA tHcy concentration. 
Kruskal-Wallis test assessed the significance of corrected birth weight percentile relationships to 
paired CV tHcy and CA tHcy concentrations. P < .05 was considered statistically significant. 
 
Results 
Maternal and Infant Characteristics 
Maternal and infant characteristics are shown in Table 1. Birth weights were appropriate for 
gestational age (>25th and <90th percentiles), and BP was consistent with reference values.31 
Chorionic Plate Arteries Distensibility and Neonatal BP Relationships to Umbilical tHcy Concentration 
To examine the passive mechanical properties of CPA, vessel dimensional changes in response to 
varying intraluminal pressures were assessed. The lumen diameter of CPA vessels expanded as 
intraluminal pressure was raised incrementally, with the most dynamic increase in lumen diameter 
occurring up to an applied pressure of 30 mm Hg (Figure 2A). Wall thickness exhibited a gradual 
decline over the same range of applied pressures (Figure 2B), with a gradual increase in wall CSA 
(Figure 2C). All CPA vessels were responsive to pressure changes, confirming preservation of 
vascular integrity. As expected, the stress-strain curve generated by CPA demonstrated an 
exponential relationship (Figure 2D), and from individual stress-strain relationship curves, the 
coefficient of vessel stiffness (b) was derived. Figure 2E shows stratification of the stress-strain 
relationship curves according to umbilical arterial tHcy concentration quartiles. The CPA vessels of 
placentas where CA plasma tHcy concentrations were in the lowest quartile demonstrated a left shift 
relative to those in higher quartiles, suggesting that these CPA vessels were stiffer (less distensible). 
Conversely, those CPA vessels from placentas with CA tHcy concentrations falling in the highest 
quartile 1 demonstrated a right shift relative to those in lower quartiles, suggesting these CPA 
vessels were less stiff with greater vessel 3 or more distensibility. As shown in Figure 2F, values of b, 
the coefficient of vessel stiffness, ranged from 2.2 to 12.2, reflecting a large variability in the 
distensible properties of CPA vessels of placentas from normal pregnancies. Vessel stiffness in 
placental CPA was inversely related to plasma tHcy concentration over the concentration range of 
4.5 to 10.8 mmol/L tHcy in CA plasma (Figure 2F), which in vivo would flow through CPA of the 
fetoplacental circulation. The concentration of tHcy in CA plasma was highly dependent upon the 
concentration of tHcy in the umbilical venous circulation as CV and CA tHcy concentrations were 
highly correlated (r2 ¼ .94, P < .001; Figure 3), in agreement with previous observations.17,35   This 
raises the possibility that tHcy arising from placental transport and/or metabolism of Hcy and 
entering the fetal circulation could ultimately influence the distensible properties of placental CPA 
vessels. Neonatal systolic, diastolic, and mean BP was not significantly associated with either CV or 
CA tHcy concentration (data not shown). 
 
Plasma tHcy, Folate, and Cbl Concentrations in Maternal and Cord Blood 
Maternal plasma tHcy, folate, and Cbl concentrations (median [quartiles], n - 23) were 4.6 [3.7, 5.9] 
mmol/L, 12.4 [6.8, 19.8] ng/mL, and 208 [163, 268] ng/L, respectively, consistent with the previous 
studies.36 In a subset of paired cord plasma samples, tHcy concentration was significantly higher in 
CV than CA plasma (6.30 [5.60, 9.95] mmol/L vs 6.10 [4.75, 8.60] mmol/ L, P = .0006) with a similar trend 
toward significance for Cbl (346 [241, 374] ng/L vs 285 [225, 352] ng/L, P < .07), while folate 
concentrations (18.15 [13.10, 38.82] ng/L vs 17.45 [12.45, 31.85] ng/L) were not significantly 
different (P =.71; n = 25 for all). CV tHcy exhibited a significant negative correlation with CV Cbl (r = 
.53, P < .005; n = 27) but not CV folate (r =.31, P = .12; n = 26), suggesting tHcy entering the fetal 
circulation was particularly modulated by Cbl. These associations were not statistically 
significant in CA plasma. 
 
Relationships of Plasma tHcy, Folate, and Cbl Concentrations in Cord Blood to Birth Weight and Neonatal Anthropometric 
Indices 
Cord venous tHcy concentration was positively correlated with birth weight, corrected birth weight 
percentile, neonate length, head circumference, and mid-arm circumference (Table 2). CV Cbl was 
negatively correlated with birth weight, corrected birth weight percentile, neonate length, and mid-
arm circumference (Table 2). CV folate demonstrated no significant relationships. Stratification of 
birth weight into percentile ranges revealed that corrected birth weight percentiles were positively 
associated with a graduated elevation of both CV and CA plasma tHcy concentrations (Figure 4). 
Discussion  
This study has revealed novel relationships between CA tHcy concentration and the 
distensibility characteristics of placental CPA that importantly provide oxygen and nutrients 
and remove waste products during development and reflect a site of vascular resistance 
within the fetoplacental circulation.37,38  We observed that CPA isolated from placentas of 
normal, uncomplicated pregnancies exhibited greater variability in their distensible properties 
as compared to other vessel types,39–42 eǀideŶĐed ďy the ǀaƌiaďility iŶ the ǀalue of β, the 
coefficient of CPA vessel stiffness (Figure 2). This variability may, however, reflect an influence 
of maternal diet; interdependencies between tHcy, folate, and Cbl can influence arterial 
stiffness. 43,44 The structural characteristics of CPA previously reported include a lack of 
internal elastic lamina and a dominance of collagen fibers orientated around the smooth 
muscle cells of the arterial wall.38  Whetheƌ gƌeateƌ iŶtƌiŶsiĐ ǀessel stiffŶess ;higheƌ β ǀalueͿ is 
underscored by changes in the content and/or arrangement of extracellular matrix proteins as 
major determinants of passive vascular mechanical properties45 requires further investigation. 
 
Previous studies examining the effects of hyperhomocysteinemia on vascular remodeling have shown 
an increased deposition of collagen and vessel stiffness leading to increased vascular resistance 
and ensuing vascular pathology.46 However, the novelty of the current study is that it has 
iŶǀestigated the ƌelatioŶships ďetǁeeŶ ǀessel CPA disteŶsiďility aŶd ͚͚physiologiĐal͛͛ ĐoŶĐeŶtƌatioŶs 
of tHcy (as accepted in clinical practice) in normal, uncomplicated pregnancy. We have 
demonstrated a clear association between these variables in matched samples, with a lower 
intrinsic stiffness and greater distensibility of placental CPA vessels found as the tHcy concentration 
in CA plasma increased (Figure 2). It was notable that the distensibility of isolated placental CPA was 
related to tHcy concentration in the umbilical arterial circulation (flowing from the fetus to the 
placenta) over a relatively narrow tHcy concentration range (4.5-10.8 mmol/L; Figure 2). Variability in 
CA plasma tHcy concentration is likely to be dictated by that in the umbilical venous circulation 
(flowing from the placenta to the fetus) based on the strong correlation between umbilical venous 
and arterial plasma tHcy concentrations (Figure 3). These observations are of interest in raising 
2 possibilities: either subtle changes in CA plasma tHcy concentration in the umbilical arterial 
circulation affects CPA vascular distensibility or greater efflux of Hcy from the placenta to the 
umbilical venous circulation occurs in placentas with greater CPA vessel distensibility. In this 
context, it is noteworthy that Hcy can elicit dilation in other vessel types in a dose-dependent 
manner.47 Homocysteine in the umbilical venous circulation could originate either from maternal 
plasma by placental transport of tHcy,48,49 with maternal tHcy concentration predicting tHcy in cord 
blood,4,35,36,50,51 or alternatively could be generated by placental metabolism, perhaps reflective of 
placental methylation capacity.1,49 However, there was no apparent influence of tHcy in the fetal 
circulation on neonatal BP, suggesting that the associations may reflect vessel-specific phenomena.  
 
We went on to consider how the relationship between tHcy and placental CPA distensibility might 
impact on fetal growth. A relatively greater CPA distensibility would be consistent with a lower 
resistance in the fetoplacental circulation, of potential benefit for placental nutrient delivery 
and fetal growth. Consistent with this concept, we observed positive associations between 
increasing tHcy concentration in both fetal circulations and birth weight outcomes (as a proxy of 
growth; Figure 4). The lack of a relationship between fetal folate concentration and birth weight 
or body size observed here in a folate-supplemented cohort is consistent with the observation 
of others who also demonstrate a lack of dependency with respect to maternal folate status.12,13,52  
 
In our study in normal pregnancy, maternal and cord plasma tHcy, folate, and Cbl concentrations 
accord well with those from previous larger studies where women routinely used folic acid 
supplements,36,50 providing confidence in the translatability of the findings. Further, the CV-CA 
tHcy relationships observed here (Figure 3) are consistent with the previous studies.17,35 Fetal 
plasma tHcy shows an inverse association with both maternal and fetal folate and Cbl 
concentrations, respectively.35,50-53 Our demonstration of a significant inverse relationship between 
tHcy and Cbl concentrations in CV plasma accords well with these previous observations,35,36,52,53 
suggesting fetal tHcy concentration is highly modulated by the availability of B-group vitamins. 
The concept of a regulatory dominance of fetal Cbl on tHcy concentration35,36,50,53  is 
strengthened here by the reciprocal associations between fetal tHcy and Cbl with respect to birth 
weight and anthropometric measurements of neonatal body size (Table 2).   
 
Importantly, our study has several strengths over the previous studies designed to investigate the 
influence of tHcy on birth weight in that we also performed measurement of anthropometric indices 
to augment determination of birth weight as a proxy of fetal growth outcome. Additionally, 
participants were a well-defined cohort of the same ethnicity, and all infants were of appropriate-for-
gestational age weight. We excluded smokers and selected women who had fetal ultrasound 
scans to confirm gestational age and who gave birth at 37 to 42 weeks, negating the effects of 
smoking and gestational age as determinants of birth weight that have associations with tHcy.10,52,54    
The strength of the association between birth weight and CV tHcy and CV Cbl was explored further 
by using corrected birth weight percentile, adjusting for maternal height, weight, ethnicity and parity, 
infant sex, and gestational age. It is notable that our findings are consistent with those of larger 
populations who have reported a negative association between Cbl status at birth with birth weight, 
length, and head circumference,52,55 suggesting these data have robust biological significance.  
 
Our evidence that birth weight and body size increase as CV tHcy concentration is raised while CV 
Cbl concentration is decreased would be compatible with an increased utilization of Cbl in the 
larger babies as a cofactor required to remethylate Hcy to methionine (Figure 1), perhaps to meet 
methylation demand1,49 and the greater rates of methionine transmethylation in late 
pregnancy.56 A higher CV tHcy concentration, reflecting greater tHcy delivery to the fetus, may 
also afford the developing fetus an opportunity to metabolize Hcy to methionine. Consistent 
with this concept, fetal uptake of Hcy is implicated by the lower CA tHcy concentration compared to 
CV tHcy, which accords with the previous observations.16,17   Additionally, the demonstration that 
methionine synthase activity is present in fetal liver and kidney57 lends support to the notion that 
the fetus has the capacity to remethylate Hcy.  
 
In summary, in normal pregnancy, umbilical plasma tHcy concentration, as a metabolite marker of 
the functioning of the methionine cycle in the fetal compartment, demonstrated a strong 
dependence on fetal Cbl, but not folate, concentration. The CPA distensibility, birth weight, and 
neonatal body size all demonstrated positive associations with fetal tHcy concentration, consistent 
with the concept of low fetoplacental vascular resistance promoting fetal growth. Further, the inverse 
associations of neonatal body size indices with fetal Cbl concentration implicate a key modulatory role 
for Cbl in regulating fetal Hcy metabolism and fetal growth, which should motivate intervention 
studies with Cbl in pregnancy. 
 
  
 Figures: 
 
Figure 1. Metabolic coupling of folate and methionine cycles. The conversion of homocysteine (Hcy) to 
methionine is crucial in generating the methyl donor S-adenosylmethionine (SAM) for methylation 
processes.  Methyl donation from SAM to cellular acceptors (R-) generates S-adenosylhomocysteine 
(SAH). The efficient metabolism of SAH (by SAH hydrolase catalysis to produce adenosine and Hcy) is essential 
as SAH inhibits the activity of SAM-dependent methyltransferases involved in a variety of methylation 
reactions. The physiological form of folate, 5-methyltetrahydrofolate (5-MTHF) serves as the methyl donor in 
the remethylation of Hcy to methionine, catalyzed by methionine synthase (MS), a cobalamin (Cbl)-
dependent enzyme. Methionine synthase is the only enzyme to utilize 5-MTHF and return tetrahydrofolate 
(THF) to the active folate pool for the de novo synthesis of purines and thymidylate for DNA synthesis. 
Tetrahydrofolate is then recycled to form 5,10-methylene tetrahydrofolate from which 5-MTHF is 
generated by the action of 5,10-methylene tetrahydrofolate reductase (MTHFR). 
 
 
 Figure 2. Relationship of the distensibility of placental chorionic plate arteries (CPAs) to umbilical arterial 
plasma total homocysteine (tHcy) concentration. Pressure myography was applied to human placental 
CPAs to investigate vascular distensibility changes in (A) vessel lumen diameter, (B) vessel wall thickness, and 
(C) vessel wall cross-sectional area (CSA) monitored in response to incremental changes in intraluminal pressure. 
This allowed calculation of (D) the stress-strain relationship, which gives an indication of the passive distensibility 
of human placental CPAs (for A-D, mean + standard error of the mean [SEM]; n = 34-38). E, Stress-strain 
relationships in CPAs stratified according to quartile concentrations of cord arterial (CA) tHcy ( , <25th [n = 
5]; , 25-75th [n = 6]; , >75th [n = 3]; mean + standard error of the mean [SEM]). F, β, calculated from the 
gradient of the stress-strain relationship and a coefficient of vessel stiffness, was inversely correlated with CA 
plasma tHcy concentration (r = - .62, P =.02, n =14; Spearman rank correlation). Values of β are shown 
according to the quartile concentrations of cord arterial tHcy ( <25th [n = 5]; , 25-75th [n = 6]; , >75th 
[n = 3]).  
 
 Figure 3. Relationship between plasma total homocysteine (tHcy) concentrations in paired samples of cord 
venous (CV) and cord arterial (CA) plasma. The concentration of tHcy was measured in paired samples of CV 
and CA plasma harvested from the umbilical cord of placentas from normal, uncomplicated pregnancies. There 
was a linear association between the concentration of tHcy in CV and CA circulations (r2 = .94, P < .0001, n = 
33).  
 
 
Figure 4. Relationship of corrected birth weight percentile to fetal plasma total homocysteine (tHcy) 
concentration in paired cord venous (CV) and cord arterial (CA) blood samples. Relationship of corrected 
birth weight percentile (birth weights adjusted for maternal height, weight, ethnicity and parity, infant sex, 
and gestational age) stratified according to <25th (n = 5), 25th to 75th (n = 12), and >75th (n = 8) 
percentiles to (A) CV plasma tHcy concentration and (B) CA plasma tHcy concentration. *P < .05, corrected 
birth weight percentile versus CA tHcy; ***P < .005, corrected birth weight percentile versus CV tHcy 
(Kruskal-Wallis test). 
 
Tables 
 
Table 1. Maternal and Newborn Infant Characteristics 
           
 
     n Median (quartiles)   
Mothers 
Age, years    49 27 (23,32)       
Parity    
1     25 
2     14 
3 or more    10 
Height, cm    49 166 (163,171) 
Weight, kg    49 67 (58,78)  
BMI     49 24 (22,27)  
Mode of delivery  
Vaginal     34  
Cesarean delivery   15  
Blood pressure, mm Hg 
Systolic     49 108  (100,115) 
Diastolic    49 64 (60,70) 
Newborn infants  
Gestational age, weeks  49 40 (39,41)  
Boys     21  
Girls     28  
Birth weight, kg    49 3.64 (3.25,4.02) 
<25     11 3.10 (2.78,3.31) 
25-75     25 3.64 (3.33,3.75) 
>75     13 4.26 (3.99,4.48) 
Length, cm    49 51.3 (50.1,53.5) 
Mid-arm circumference, cm  49 11.2 (10.6,12.1) 
Occipitofrontal circumference, cm 49 35.4 (34.5,36.0) 
Blood pressure, mm Hg 
Systolic     49 78 (71,85) 
Diastolic    49 43 (36,49) 
Mean     49 53 (47,62) 
Heart rate per minute   49 131 (121,142) 
Cord venous blood 
Plasma tHcy, mmol/L   38 6.25 (5.10,9.95) 
Plasma folate, ng/mL   27 22.05 (14.20,35.35) 
Plasma Cbl, ng/L    28 348 (266,377) 
Cord arterial blood 
Plasma tHcy, mmol/L   29 6.30 (5.10,10.45) 
Plasma folate, ng/mL   14 17.45 (12.45,31.85) 
Plasma Cbl (ng/L)   14 284 (225,352) 
 
 
Abbreviations: BMI, body mass index; Cbl, cobalamin; tHcy, total homocysteine.    
aCorrected birth weight percentile: birth weight was adjusted for maternal height, weight, ethnicity, and 
parity, infant sex, and gestational age. 
 
 
Table 2. Relationships Between Plasma tHcy, Folate, and Cbl    Concentrations in CV Plasma and Birth 
Weight and Anthropometric Measurements in Newborns.  
 
      CV Plasma      
 
Infant Size  tHcy, mmol/L  Folate, ng/mL  Cbl, ng/L  
 
Birth weight, kg 
 r (n)  .67 (36)   -0.01 (27)  -0.43 (28) 
 P  <.0001a   .96   .022a 
Corrected birth weight percentile 
 r (n)  -.59 (36)  -.05 (27)  -.51 (28) 
 P  .0001a   .81   .005a 
Length, cm 
 r (n)  .48 (36)   .26 (27)   -.43 (28) 
 P  .003a   .19   .022a 
Occipitofrontal head circumference, cm 
 r (n)  .43 (36)   -.15 (27)  -.29 (28) 
 P  .0087a   .46   .14 
Mid-arm circumference, cm 
 r (n)  .47 (36)   .05 (27)   -.55 (28) 
 P  .004a   .81   .0024a 
 
Abbreviations: Cbl, cobalamin; CV, cord venous; r (n): Spearman correlation (number of newborn infants); 
tHcy, total homocysteine.    
aDenotes statistical significance. 
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